Document is current

Any future updates will be listed below

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

Crossref DOI link: https://doi.org/10.1186/s10194-021-01307-6

Published Online: 2021-08-26

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark